Abstract
Depression is a leading cause of morbidity and mortality, and its treatment includes a high percentage of the medications prescribed by physicians. Available antidepressant drugs are safe and effective, but less than half of all patients attain complete remission after therapy with a single antidepressant. Others exhibit partial, refractory or intolerant responses to treatment, emphasizing the need to discover new antidepressants. The mechanisms of action of available medications are directing the field toward new research avenues. This review highlights those areas we believe will influence the field and soon lead to better treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kessler, R.C. et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch. Gen. Psychiatry 51, 8–19 (1994).
Blazer, D.G. et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am. J. Psychiatry 151, 979–986 (1994).
Murray, C.J.L. & Lopez, A.D. (eds.) The Global Burden of Disease (Harvard Univ. Press, Boston, 1996).
Klerman, G.L. et al. Birth-cohort trends in rates of major depressive disorder among relatives of patients with affective disorder. Arch. Gen. Psychiatry 42, 689–693 (1985).
Musselman, D.L., Evans, D.L. & Nemeroff, C.B. The relationship of depression to cardiovascular disease: diagnosis, biology and treatment. Arch. Gen. Psychiatry 55, 580–592 (1998).
Frasure-Smith, N., Lesperance, F. & Talajic, M. Depression following myocardial infarction: impact on 6-month survival. JAMA 270, 1819–1825 (1993).
Frasure-Smith, N., Lesperance, F. & Talajic, M. Depression and 18-month prognosis after myocardial infarction. Circulation 91, 999–1005 (1995).
Sanders, A.R., Detera-Wadleigh, S.D. & Gershon, E.S. in Neurobiology of Mental Illness (eds. Charney, D. S., Nestler, E. J. & Bunne,y B. S.) 299–316 (Oxford Univ. Press, New York, 1999).
Duman, R.S., Heninger, G.R. & Nestler, E.J. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54, 597–606 (1997).
Thome, J. et al. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 20, 4030–4036 (2000).
Entsuah, A.R., Huang, H. & Thase, M.E. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J. Clin. Psychiatry 62, 869–877 (2001).
Thase, M.E., Entsuah, A.R. & Rudolph, R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 178, 234–241 (2001).
Owens, M.J. & Nemeroff, C.B. The serotonin transporter and depression. Depress. Anxiety 8(S1), 5–12 (1998).
Ressler, K.J. & Nemeroff, C.B. Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol. Psychiatry 46, 1219–1233 (1999).
Meyer, J.H. et al. Lower dopamine transporter binding potential in striatum during depression. NeuroReport 12, 4121–4125 (2001.)
Anderson, I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disorders 58, 19–36 (2000).
Gilmor, M.L., Owens, M.J. & Nemeroff, C.B. Inhibition of norepinephrine uptake in patients with major depression treated with the selective serotonin reuptake inhibitor paroxetine. Am. J. Psychiatry (in press).
Owens, M.J. et al. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J. Pharmacol. Exp. Ther. 283, 1305–1322 (1997).
Blier, B. Pharmacology of rapid-onset antidepressant treatment strategies. J. Clin. Psychiatry 62(S15), 12–17 (2001).
Rabiner, E.A. et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am. J. Psychiatry 158, 2080–2082 (2001).
Owens, M.J. & Nemeroff, C.B. Physiology and pharmacology of corticotropin-releasing factor. Pharmacol. Rev. 43, 425–473 (1991).
Reul, J.M. & Holsboer, F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2, 23–33 (2002).
Zobel, A.W. et al. Effects of the high affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatry Res. 34, 171–181 (2000).
Belanoff, J.K., Flores, B.H., Kalezhan, M., Sund, B. & Schatzberg, A.F. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21, 516–521 (2001).
Kramer, M.S. et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640–1645 (1998).
Stout, S.C., Owens, M.J. & Nemeroff, C.B. Neurokinin1 receptor antagonists as potential antidepressants. Ann. Rev. Pharmacol. Toxicol. 41, 877–906 (2001).
Meyer, J.H. et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [11C]DASB PET imaging study. Am. J. Psychiatry 158, 1843–1849 (2001).
Acknowledgements
Supported by NIH grants MH42088, MH39415 and the Conte Center for the Neuroscience of Mental Disorders (MH58922).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nemeroff, C., Owens, M. Treatment of mood disorders. Nat Neurosci 5 (Suppl 11), 1068–1070 (2002). https://doi.org/10.1038/nn943
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nn943
This article is cited by
-
Self-immolative nanocapsules precisely regulate depressive neuronal microenvironment for synergistic antidepression therapy
Journal of Nanobiotechnology (2023)
-
Prenatal Hypoxia-Induced Adverse Reaction to Mild Stress is Associated with Depressive-Like Changes in the Glucocorticoid System of Rats
Neurochemical Research (2023)
-
Neuroadaptations and TGF-β signaling: emerging role in models of neuropsychiatric disorders
Molecular Psychiatry (2022)
-
Reduced Firing of Nucleus Accumbens Parvalbumin Interneurons Impairs Risk Avoidance in DISC1 Transgenic Mice
Neuroscience Bulletin (2021)
-
Molecular and biological functions of resveratrol in psychiatric disorders: a review of recent evidence
Cell & Bioscience (2020)